Molecular genetic analysis of HLA class II alleles in Japanese patients with melanoma

Tissue Antigens

Volumn 49, Issue 5, 1997, Pages 466-470

  Kageshita, T ^a   Naruse, T ^b   Hirai, S ^a   Ono, T ^a   Horikoshi, T ^c   Nakagawa, H ^d   Tamaki, K ^d   Hayashibe, K ^e   Ichihashi, M ^e   Nakayama, J ^f   Hori, Y ^f   Ozawa, A ^b   Miyahara, M ^b   Ohkido, M ^b   Inoko, H ^b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b TOKAI UNIVERSITY   (Japan)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e KOBE UNIVERSITY   (Japan)

^f KYUSHU UNIVERSITY   (Japan)

Author keywords

HLA class II; Japanese melanoma; PCR RFLP

Indexed keywords

HLA ANTIGEN CLASS 2; HLA DP ANTIGEN; HLA DQ ANTIGEN;

ADULT; AGED; ALLELE; ARTICLE; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; HLA TYPING; HUMAN; HUMAN TISSUE; JAPAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PATIENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 8244232507     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0039.1997.tb02780.x     Document Type: Article

References (19)

1. Darrow TL, Sllingluff CL, Seigier HF. The role of HLA class 1 antigens in recognition of melanoma cells by tumor-specific cytotoxic T-lymphocytes: evidence for shared tumor antigens. J Immunol 1989: 142: 3329-3335.
2. Marincola FM, Venzon D, White D et al. HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy. Cancer Res 1992: 52: 6561-6566.
3. Mueller-Eckhardt G, Schendel DJ, Hundeiker M et al. Possible association between HLA-DR5 and superficial spreading melanoma. Int J Cancer 1984: 34: 751-755.
4. Barger BO, Acton RT, Soong S-J, Roseman J, Balch C. Increase of HLA-DR4 in melanoma patients from Alabama. Cancer Res 1982: 42: 4276-4279.
5. Mytilineos J, Scherrer S, Opelz G. Comparison of RFLP-DR beta and serological HLA-DR typing in 1500 individuals. Transplantation 1990: 50: 870-873.
6. Reveille JD, Durban E, MacLeod-St Clair MJ et al. Association of amino acid sequences in the HLA-DQB1 first domain with the antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis). J Clin Invest 1992: 90: 973-980.
7. Lee JE, Reveille JD, Ross MI, Platsoucas CD. HLA-DQB1*0301 association with increased cutaneous melanoma risk. Int J Cancer 1994: 59: 510-513.
8. Marincola FM, Shamamian P, Rivoltini L et al. HLA associations in the antitumor response against malignant melanoma. J Immunother 1996: 18: 242-252.
9. Inoko H, Ando A, Ito M, Tsuji K. Southern hybridization of DNA polymorphism in the HLA-D region. Hum Immunol 1986: 16: 304-313.
10. Nomura M, Ota M, Tsuji K, Inoko H. HLA-DQB1 genotyping by PCR-RFLP method combimed with group-specific primers. Tissue Antigens 1991: 38: 53-59.
11. Ota M, Seki T, Nomura N et al. Modified PCR-RFLP method for HLA-DPB1 and -DQA1 genotyping. Tissue Antigens 1991: 38: 60-71.
12. Ota M, Seki T, Fukushima H, Tsuji K, Inoko H. HLA-DRB1 genotyping by modified PCR-RFLP method combined with group-specific primers. Tissue Antigens 1992: 39: 187-202.
13. Inoko H, Ota M. PCR-RFLP. In: Hui KM, Bidwell JL, ed. Handbook of HLA typing techniques 1993. Boca Raton, FL: CRC Press, 1993: 9-70.
14. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, ed. Manual for staging of cancer. American Joint Committee on Cancer. 4th edn. Philadelphia: JB Lippincott Co., 1992: 143-148.
15. Streilein JW. Immunogenetic factors in skin cancer. N Engl J Med 1991: 325: 884-886.
16. Klitz W. Viruses, cancer and MHC. Nature 1992: 356: 17-18.
17. Kripke ML. Speculations on the role of ultraviolet radiation in the development of malignant melanoma. J Natl Cancer Inst 1979: 63: 541-545.
18. Kageshita T, Nakamura T, Yamada M, Kuriya N, Arao T, Ferrone S. Differential expression of melanoma associated antigens in acral lentiginous melanoma and in nodular melanoma. Cancer Res 1991: 51: 1726-1732.
19. Lee JE, Lu M, Mansfield PF, Platsoucas CD, Reveille JD, Ross MI. Malignant melanoma: relationship of the human leukocyte antigen class II gene DQB1*0301 to disease recurrence in American Joint Committee on Cancer stage I or II. Cancer 1996: 78: 758-763.